Regado Biosciences

Regado Biosciences, Inc. is a biopharmaceutical company focused on developing novel, first-in-class, actively controllable antithrombotic drug systems for acute and subacute cardiovascular indications. Regado is pioneering the development of two-component drug systems consisting of therapeutic aptamers and their specific active control agents. The company's lead product candidate, REG1, is a two-component system comprised of pegnivacogin (an anticoagulant aptamer specifically targeting coagulation factor IXa) and its complementary oligonucleotide active control agent, anivamersen. REG1 is currently being evaluated in the REGULATE-PCI trial.